S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report
Megan Othus,Stefan Faderl,Derek L. Stirewalt,Sherry Pierce,Gautam Borthakur,John E. Godwin,Jeanne E. Anderson,Stephen H. Petersdorf,Jorge E. Cortes,Fabiana Ostronoff,Era Pogosova-Agadijanyan,Frederick R. Appelbaum,Hagop M. Kantarjian,Elihu H. Estey +13 more
TL;DR: Patients with normal cytogenetics/ NPM 1 mutated/ FLT3 -ITD negative AML clearly have more favorable outcomes and, hence, are potentially a group that might benefit from HDAC therapy, and this possibility is examined.
Journal ArticleDOI
Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia
Naveen Pemmaraju,Hagop M. Kantarjian,Susan O'Brien,Tapan M. Kadia,Jorge E. Cortes,Gautam Borthakur,Stefan Faderl,Guillermo Garcia-Manero,Zeev Estrov,Farhad Ravandi,Alfonso Quintás-Cardama,Elias Jabbour,Charles Koller,Sara Dellasala,Sherry Pierce,Elizabeth M. Burton,Srdan Verstovsek +16 more
TL;DR: To determine safety, maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of ruxolitinib in treatment of relapsed/refractory acute leukemia pts (AML or ALL), a single-center prospective phase I clinical trial.
Journal ArticleDOI
Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)
TL;DR: A Q-TWiST analysis of the phase 3 study to compare survival between patients receiving CPX-351 versus 7+3 found that the OS benefit was maintained and the means difference was 95% CI.
Journal ArticleDOI
Complete Eradication of Minimal Residual Disease (MRD) in Patients with Hairy Cell Leukemia (HCL) after Cladribine (2CDA) Followed by an Extended Course of Rituximab.
Farhad Ravandi-Kashani,Susan O'Brien,Keating Michael,Dan Jones,Stefan Faderl,Alessandra Ferrajoli,William G. Wierda,Shirley Odinga,Sherry Pierce,Charles Koller,Srdan Verstovsek,Jeffrey L. Jorgensen,Hagop M. Kantarjian +12 more
TL;DR: It is concluded that therapy with an extended course of rituximab is effective in eradicating MRD in HCL and the predictive value of achievement of negative MRD, presence of chromosome 17 abnormalities, or the mutational status of IgVH on the risk of relapse should be evaluated in larger series and with longer follow-up.
Journal ArticleDOI
Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy
Farhad Ravandi,Jean Pierre J. Issa,Guillermo Garcia-Manero,Susan O'Brien,Sherry Pierce,Jenny Shan,Srdan Verstovsek,Stefan Faderl,Jorge E. Cortes,Hagop M. Kantarjian +9 more
TL;DR: It is concluded that treatment with hypomethylating agents may be superior to chemotherapy in patients with chromosome 5 and 7 abnormalities who are traditionally resistant to cytotoxic agents.